Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares |
3 Months Ended | 12 Months Ended |
|---|---|---|
Mar. 31, 2026 |
Dec. 31, 2025 |
|
| Statement of Financial Position [Abstract] | ||
| Common stock, no par value (in dollars per share) | $ 0 | $ 0 |
| Common Stock, Shares Authorized, Unlimited [Fixed List] | Unlimited | Unlimited |
| Common stock, shares issued (in shares) | 303,945,581 | 300,600,710 |
| Common stock, shares outstanding (in shares) | 303,945,581 | 300,600,710 |
Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands |
Total |
Common Shares |
Additional Paid-in Capital |
Accumulated Earnings (Deficit) |
Accumulated Other Comprehensive Loss |
|---|---|---|---|---|---|
| Beginning balances (in shares) at Dec. 31, 2024 | 295,757,002 | ||||
| Beginning balances at Dec. 31, 2024 | $ 1,056,084 | $ 777,171 | $ 166,361 | $ 116,930 | $ (4,378) |
| Number of Shares | |||||
| Shares issued and restricted stock units ("RSUs") vested under stock option plan (in shares) | 2,598,750 | ||||
| Shares issued and restricted stock units (“RSUs”) vested under stock option plan | 151 | $ 12,897 | (12,746) | ||
| Stock-based compensation | 14,988 | 14,988 | |||
| Foreign currency translation adjustment | (2,620) | (2,620) | |||
| Net loss | (45,621) | (45,621) | |||
| Ending balances (in shares) at Mar. 31, 2025 | 298,355,752 | ||||
| Ending balances at Mar. 31, 2025 | 1,022,982 | $ 790,068 | 168,603 | 71,309 | (6,998) |
| Beginning balances (in shares) at Dec. 31, 2025 | 300,600,710 | ||||
| Beginning balances at Dec. 31, 2025 | 966,904 | $ 802,341 | 198,279 | (29,482) | (4,234) |
| Number of Shares | |||||
| Shares issued and restricted stock units ("RSUs") vested under stock option plan (in shares) | 3,344,871 | ||||
| Shares issued and restricted stock units (“RSUs”) vested under stock option plan | 516 | $ 14,192 | (13,676) | ||
| Stock-based compensation | 12,013 | 12,013 | |||
| Foreign currency translation adjustment | 1,815 | 1,815 | |||
| Net loss | (43,165) | (43,165) | |||
| Ending balances (in shares) at Mar. 31, 2026 | 303,945,581 | ||||
| Ending balances at Mar. 31, 2026 | $ 938,083 | $ 816,533 | $ 196,616 | $ (72,647) | $ (2,419) |
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Cash flows from operating activities: | ||
| Net loss | $ (43,165) | $ (45,621) |
| Cash flows from operating activities: | ||
| Depreciation of property and equipment | 5,918 | 4,409 |
| Amortization of intangible assets | 920 | 922 |
| Amortization of operating lease right-of-use assets | 1,817 | 1,274 |
| Stock-based compensation | 12,013 | 14,786 |
| Other | 2,377 | 2,213 |
| Changes in operating assets and liabilities: | ||
| Research fees and grants receivable | 13,103 | (1,133) |
| Income taxes payable | (4,970) | (4,408) |
| Accounts payable and accrued liabilities | (9,406) | (3,409) |
| Deferred revenue | (8,033) | 13,313 |
| Deferred grant income | (2,356) | (1,220) |
| Other assets | (1,741) | 7,320 |
| Net cash used in operating activities | (33,523) | (11,554) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (3,831) | (10,636) |
| Purchase of marketable securities | (166,308) | (164,990) |
| Proceeds from marketable securities | 143,802 | 190,027 |
| Receipt of grant funding | 1,361 | 1,018 |
| Long-term investments and other assets | (105) | (7,484) |
| Net cash provided by (used in) investing activities | (25,081) | 7,935 |
| Cash flows from financing activities: | ||
| Proceeds from long-term liabilities and other | 7,192 | 5,970 |
| Net cash provided by financing activities | 7,192 | 5,970 |
| Effect of exchange rate changes on cash and cash equivalents | (38) | 590 |
| Increase (decrease) in cash and cash equivalents | (51,450) | 2,941 |
| Cash and cash equivalents and restricted cash, beginning of period | 155,249 | 183,615 |
| Cash and cash equivalents and restricted cash, end of period | 103,799 | 186,556 |
| Restricted cash included in other assets | 1,736 | 2,290 |
| Total cash, cash equivalents, and restricted cash shown on the balance sheet | 102,063 | 184,266 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Property and equipment in accounts payable | 706 | 10,960 |
| Right-of-use assets obtained in exchange for operating lease obligation | $ 0 | $ 3,361 |
Nature of operations |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| Nature of operations | Nature of operations AbCellera Biologics Inc.’s (the “Company”) is a clinical-stage biotechnology company focused on discovering and developing antibody medicines for indications with high unmet medical need. The Company aims to bring antibody drug candidates from target to clinic by combining expertise, technologies, and infrastructure for antibody drug discovery and development. The Company uses its capabilities to develop its own pipeline of future antibody drugs and has a diversified portfolio of royalty (and equivalent) stakes in future antibody drugs with partners.
|
Basis of presentation |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| Basis of presentation | Basis of presentation The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2025. These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March 31, 2025 and 2026 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2025. All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.
|
Significant accounting policies |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Accounting Policies [Abstract] | |
| Significant accounting policies | Significant accounting policies Use of estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, the impairment assessment of intangible assets and goodwill, and the estimates associated with stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates. Recent accounting pronouncements The Company has reviewed recent accounting pronouncements in the three months ended March 31, 2026 and concluded that they are either not applicable to the Company or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.
|
Net loss per share |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss per share | Net loss per share Basic and diluted net loss per share was calculated as follows:
The Company’s potentially dilutive securities, which include stock options and restricted share units (“RSUs”), have been excluded from the computation of diluted net loss per share for the three months ended March 31, 2025 and March 31, 2026 as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three months ended March 31, 2025 and March 31, 2026 used to calculate both basic and diluted net loss per share is the same. The Company excluded 71,947,646 and 79,140,601 potential common shares for the three months ended March 31, 2025 and 2026, respectively, from the computation of diluted net loss per share because including them would have had an anti-dilutive effect.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and equipment, net |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property and equipment, net | Property and equipment, net Property and equipment, net consisted of the following:
Depreciation expense on property and equipment for the three months ended March 31, 2025 and 2026 was $4.4 million and $5.9 million, respectively.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible assets |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible assets | Intangible assets Intangible assets consisted of the following:
Amortization expense on intangible assets subject to amortization is estimated to be as follows for each of the next five years ended March 31:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments in equity accounted investees, and other assets |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Equity Method Investments and Joint Ventures [Abstract] | |
| Investments in equity accounted investees, and other assets | Investments in equity accounted investees and other assets The Company has entered into two separate 50% joint ventures, Dayhu JV and Beedie JV, as part of the construction of new office and laboratory headquarters. The Company recorded immaterial amounts of proportionate income or loss with respect to either venture in the three months ended March 31, 2025 and 2026. Dayhu JV As of December 31, 2025 and March 31, 2026, the equity investment balance was $10.8 million and $11.5 million, respectively, of which substantially all the assets in the Dayhu JV are comprised of property and equipment. As of December 31, 2025 and March 31, 2026, the Company recorded a right-of-use asset of $45.9 million and $45.2 million, respectively, and an operating lease liability of $46.7 million and $45.6 million, respectively, associated with an office lease with the Dayhu JV. In the three months ended March 31, 2025 and 2026, the Company incurred lease expense of $1.2 million and $1.3 million, respectively, to the Dayhu JV included within operating expenses. As of December 31, 2025 and March 31, 2026, the Dayhu JV’s fixed-rate mortgage had a balance of $61.2 million and $60.2 million, respectively. The Company provides a limited guarantee of the JV's loan obligations, capped at CAD $42.0 million ($30.6 million), which matches a corresponding guarantee provided by the Dayhu JV partner. Beedie JV As of December 31, 2025 and March 31, 2026, the equity investment balance was $51.8 million and $53.8 million, respectively, of which substantially all the assets in the Beedie JV are comprised of property and equipment. As of December 31, 2025 and March 31, 2026, the Company recorded a right-of-use asset of $71.5 million and $71.0 million, respectively, and an operating lease liability of $75.7 million and $74.4 million, respectively, associated with an office lease with the Beedie JV. In the three months ended March 31, 2025 and 2026, the Company incurred lease expense of nil and $1.8 million, respectively, to the Beedie JV included within operating expenses. The Company had a loan receivable balance of $39.4 million and $39.2 million at December 31, 2025 and March 31, 2026, respectively, included within other current assets. The loan receivable is directly with our JV partner, Beedie, which relates to the land and construction loan that matures in February 2027.
|
Other current assets and liabilities |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Payables and Accruals [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other current assets and liabilities | Other current assets and liabilities Other current assets
Current accounts payable and other current liabilities
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shareholders’ equity |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-Based Payment Arrangement [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shareholders' equity | Shareholders’ equity The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2025:
The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2025:
The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2025:
As of March 31, 2026, the number of shares available for issuance under the 2020 Plan was 33,758,986, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020. Stock-based compensation: Stock-based compensation was classified in the condensed consolidated statements of loss and comprehensive loss as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue from Contract with Customer [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue | Revenue The disaggregated revenue categories are presented on the face of the condensed consolidated statements of loss and comprehensive loss. Deferred revenue outstanding in each respective period is as follows:
During the three months ended March 31, 2025 and 2026, the Company recognized $2.6 million, and $7.9 million, respectively, that was included in deferred revenue at the end of the preceding periods. Additionally, during the three months ended March 31, 2026, the Company collected $18.0 million of the $36.0 million litigation settlement receivable outstanding as of December 31, 2025.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial instruments |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments, All Other Investments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial instruments | Financial instruments Fair Value Measurements The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market. The Company’s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, loans receivable, and accounts payable and other liabilities. The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and other liabilities, and loans receivable, approximate their fair values, and are primarily classified as Level 2. At March 31, 2026, the Company also held non-marketable securities included in other long-term assets of $32.5 million (December 31, 2025 - $32.5 million). These non-marketable securities are measured at cost less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. Marketable Securities As part of the Company’s cash management strategy, the Company holds high credit quality marketable securities that are available to support the Company’s current operations. As of March 31, 2026, our marketable securities were rated A- or higher (or its equivalent) by at least two of the major rating agencies with a weighted average life of approximately 0.6 years. Level 2 marketable securities in the fair value hierarchy were based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. There were no transfers between Level 1, Level 2 and Level 3 during the period. The following table presents information about the Company’s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and contingencies |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Commitments and Contingencies Disclosure [Abstract] | |
| Commitments and contingencies | Commitments and contingencies From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred. The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include investments in collaborative arrangements, contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements. Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upon receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. Immaterial amounts were expensed during the three months ended March 31, 2025 or March 31, 2026.
|
Government Contributions |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Government Assistance [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Government contributions | Government contributions The Company recognized the following on the consolidated balance sheets:
1No amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable. 2As of December 31, 2024, the Company had incurred the maximum expenditures under the agreement. Repayment of CAD $116.9 million ($88.5 million) of the funded amount is conditional on achieving certain revenue thresholds over a specified period of time. 3The funding includes repayable and conditionally repayable amounts starting in 2033 over 15 years, where the conditional portion is based on certain revenue thresholds, at a factor of up to 1.4 times the original grant. As of March 31, 2026, total available undrawn grant funding was approximately CAD $111.8 million ($80.2 million), consisting of CAD $94.4 million ($67.8 million) for future qualifying expenditures and $12.5 million in accrued grants receivable for which claims will be filed subsequently. 4Conditionally repayable amounts starting in 2032 over up to fifteen years, based on certain revenue thresholds. As of March 31, 2026, total available undrawn grant funding was approximately CAD $60.2 million ($43.2 million), consisting of CAD $35.5 million ($25.5 million) for future qualifying expenditures and $17.7 million in accrued grants receivable for which claims will be filed subsequently. 5During the three months ended March 31, 2026, the Company recognized non-cash investing and financing activities for uncollected government grants of $0.2 million and $4.9 million, respectively (2025: $0.8 million and $8.3 million).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Insider Trading Arrangements |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Trading Arrangements, by Individual | |
| Rule 10b5-1 Arrangement Adopted | false |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
Significant accounting policies (Policies) |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Accounting Policies [Abstract] | |
| Basis of presentation | The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2025.
|
| Consolidation | The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2025.
|
| Use of estimates | Use of estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, the impairment assessment of intangible assets and goodwill, and the estimates associated with stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.
|
| Recent accounting pronouncements | Recent accounting pronouncements The Company has reviewed recent accounting pronouncements in the three months ended March 31, 2026 and concluded that they are either not applicable to the Company or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.
|
Net loss per share (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Basic and Diluted Net Loss Per Share | Basic and diluted net loss per share was calculated as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and equipment, net (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Property and Equipment, Net | Property and equipment, net consisted of the following:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible assets (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Intangible Assets | Intangible assets consisted of the following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Estimated Amortization Expense on Intangible Assets | Amortization expense on intangible assets subject to amortization is estimated to be as follows for each of the next five years ended March 31:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other current assets and liabilities (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Payables and Accruals [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Other Current Assets | Other current assets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Current Accounts Payable and Other Current Liabilities | Current accounts payable and other current liabilities
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shareholders’ equity (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-Based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Stock Option Activity | The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2025:
The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2025:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Restricted Share Units Activity | The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2025:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Stock-Based Compensation Expense | Stock-based compensation was classified in the condensed consolidated statements of loss and comprehensive loss as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue from Contract with Customer [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Deferred Revenue Outstanding | Deferred revenue outstanding in each respective period is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial instruments (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments, All Other Investments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Financial Assets Measured at Fair Value on Recurring Basis | The following table presents information about the Company’s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Government contributions (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Government Assistance [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Government Assistance | The Company recognized the following on the consolidated balance sheets:
1No amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable. 2As of December 31, 2024, the Company had incurred the maximum expenditures under the agreement. Repayment of CAD $116.9 million ($88.5 million) of the funded amount is conditional on achieving certain revenue thresholds over a specified period of time. 3The funding includes repayable and conditionally repayable amounts starting in 2033 over 15 years, where the conditional portion is based on certain revenue thresholds, at a factor of up to 1.4 times the original grant. As of March 31, 2026, total available undrawn grant funding was approximately CAD $111.8 million ($80.2 million), consisting of CAD $94.4 million ($67.8 million) for future qualifying expenditures and $12.5 million in accrued grants receivable for which claims will be filed subsequently. 4Conditionally repayable amounts starting in 2032 over up to fifteen years, based on certain revenue thresholds. As of March 31, 2026, total available undrawn grant funding was approximately CAD $60.2 million ($43.2 million), consisting of CAD $35.5 million ($25.5 million) for future qualifying expenditures and $17.7 million in accrued grants receivable for which claims will be filed subsequently. 5During the three months ended March 31, 2026, the Company recognized non-cash investing and financing activities for uncollected government grants of $0.2 million and $4.9 million, respectively (2025: $0.8 million and $8.3 million).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss per share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Basic loss per share | ||
| Net loss | $ (43,165) | $ (45,621) |
| Weighted-average common shares outstanding - basic (in shares) | 303,074,605 | 297,692,663 |
| Net loss per share - basic (in dollars per share) | $ (0.14) | $ (0.15) |
| Diluted loss per share | ||
| Net loss | $ (43,165) | $ (45,621) |
| Weighted-average common shares outstanding - diluted (in shares) | 303,074,605 | 297,692,663 |
| Net loss per share - diluted (in dollars per share) | $ (0.14) | $ (0.15) |
Net loss per share - Additional Information (Details) - shares |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Earnings Per Share [Abstract] | ||
| Total potential common shares excluded (in shares) | 79,140,601 | 71,947,646 |
Property and equipment, net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands |
Mar. 31, 2026 |
Dec. 31, 2025 |
|---|---|---|
| Property Plant And Equipment [Line Items] | ||
| Operating lease right-of-use assets | $ 134,300 | $ 136,117 |
| Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] | Property and equipment, net | Property and equipment, net |
| Property and equipment | $ 486,340 | $ 485,617 |
| Less: accumulated depreciation | (63,534) | (57,614) |
| Property and equipment, net | 422,806 | 428,003 |
| Land | ||
| Property Plant And Equipment [Line Items] | ||
| Property and equipment, gross | 53,405 | 53,405 |
| Building and building improvements | ||
| Property Plant And Equipment [Line Items] | ||
| Property and equipment, gross | 194,834 | 193,160 |
| Equipment | ||
| Property Plant And Equipment [Line Items] | ||
| Property and equipment, gross | $ 103,801 | $ 102,935 |
Property and equipment, net - Additional Information (Details) - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Property, Plant and Equipment [Abstract] | ||
| Depreciation expense on property and equipment | $ 5,918 | $ 4,409 |
Intangible assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands |
Mar. 31, 2026 |
Dec. 31, 2025 |
|---|---|---|
| Finite Lived Intangible Assets [Line Items] | ||
| Gross carrying amount | $ 69,320 | $ 69,320 |
| Accumulated amortization | 31,860 | 30,939 |
| Net book value | 37,460 | 38,381 |
| License | ||
| Finite Lived Intangible Assets [Line Items] | ||
| Gross carrying amount | 16,620 | 16,620 |
| Accumulated amortization | 9,370 | 8,968 |
| Net book value | 7,250 | 7,652 |
| Technology | ||
| Finite Lived Intangible Assets [Line Items] | ||
| Gross carrying amount | 52,700 | 52,700 |
| Accumulated amortization | 22,490 | 21,971 |
| Net book value | $ 30,210 | $ 30,729 |
Intangible assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details) $ in Thousands |
Mar. 31, 2026
USD ($)
|
|---|---|
| Amortization Expense | |
| 2027 | $ 3,732 |
| 2028 | 3,732 |
| 2029 | 3,732 |
| 2030 | 3,686 |
| 2031 | 2,326 |
| Finite lived intangible assets amortization expense | $ 17,208 |
Investments in equity accounted investees, and other assets (Details) $ in Thousands, $ in Millions |
3 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
|
Mar. 31, 2026
USD ($)
jointVenture
|
Mar. 31, 2026
CAD ($)
jointVenture
|
Mar. 31, 2025
USD ($)
|
Dec. 31, 2025
CAD ($)
|
Dec. 31, 2025
USD ($)
|
|
| Schedule Of Equity Method Investments [Line Items] | |||||
| Number of joint ventures | jointVenture | 2 | 2 | |||
| Operating lease right-of-use assets | $ 134,300 | $ 136,117 | |||
| Dayhu JV | |||||
| Schedule Of Equity Method Investments [Line Items] | |||||
| Equity method investments, ownership percent | 50.00% | ||||
| Equity investment balance, contributions made in joint venture | $ 11,500 | 10,800 | |||
| Operating lease right-of-use assets | 45,200 | 45,900 | |||
| Lease liability | 45,600 | 46,700 | |||
| Lease expense | 1,300 | $ 1,200 | |||
| Fixed rate mortgage | $ 60,200 | 61,200 | |||
| Dayhu JV | Daylu JV Loan | |||||
| Schedule Of Equity Method Investments [Line Items] | |||||
| Equity method investment commitment amount | $ 30.6 | $ 42.0 | |||
| Beedie JV | |||||
| Schedule Of Equity Method Investments [Line Items] | |||||
| Equity method investments, ownership percent | 50.00% | ||||
| Equity investment balance, contributions made in joint venture | $ 53,800 | 51,800 | |||
| Operating lease right-of-use assets | 71,000 | 71,500 | |||
| Lease liability | 74,400 | 75,700 | |||
| Lease expense | 1,800 | $ 0 | |||
| Loan receivable | $ 39,200 | $ 39,400 | |||
Other current assets and liabilities - Other Current Assets (Details) - USD ($) $ in Thousands |
Mar. 31, 2026 |
Dec. 31, 2025 |
|---|---|---|
| Payables and Accruals [Abstract] | ||
| Taxes receivable | $ 39,800 | $ 55,695 |
| Prepaid expenses and other | 11,279 | 9,670 |
| Materials and supplies | 7,860 | 6,336 |
| Loans receivable from JV partners | 39,164 | 39,412 |
| Total other current assets | $ 98,103 | $ 111,113 |
Other current assets and liabilities - Schedule of Accounts Payable and Other Current Liabilities (Details) - USD ($) $ in Thousands |
Mar. 31, 2026 |
Dec. 31, 2025 |
|---|---|---|
| Payables and Accruals [Abstract] | ||
| Accounts payable and accrued liabilities | $ 20,808 | $ 25,228 |
| Current portion of operating lease liability | $ 5,869 | $ 5,815 |
| Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Total accounts payable and other current liabilities | Total accounts payable and other current liabilities |
| Payroll liabilities | $ 3,926 | $ 10,755 |
| Current portion of deferred government contribution | 8,948 | 8,983 |
| Total accounts payable and other current liabilities | $ 39,551 | $ 50,781 |
Shareholders’ equity - Schedule of Stock Option Activity (Details) |
3 Months Ended |
|---|---|
|
Mar. 31, 2026
$ / shares
shares
| |
| Pre-IPO Plan | |
| Number of Shares | |
| Outstanding, beginning balance (in shares) | shares | 24,089,219 |
| Granted (in shares) | shares | 0 |
| Exercised (in shares) | shares | (825,281) |
| Forfeited (in shares) | shares | 0 |
| Outstanding, ending balance (in shares) | shares | 23,263,938 |
| Options exercisable (in shares) | shares | 23,263,938 |
| Weighted- Average Exercise Price | |
| Outstanding, beginning balance (in dollars per share) | $ / shares | $ 1.07 |
| Granted (in dollars per share) | $ / shares | 0 |
| Exercised (in dollars per share) | $ / shares | 0.22 |
| Forfeited (in dollars per share) | $ / shares | 0 |
| Outstanding, ending balance (in dollars per share) | $ / shares | 1.10 |
| Weighted- Average Exercise Price, Options exercisable (in dollars per share) | $ / shares | $ 1.10 |
| 2020 Share Option and Incentive Plan | |
| Number of Shares | |
| Outstanding, beginning balance (in shares) | shares | 36,376,041 |
| Granted (in shares) | shares | 10,103,558 |
| Exercised (in shares) | shares | (103,287) |
| Forfeited (in shares) | shares | (640,277) |
| Outstanding, ending balance (in shares) | shares | 45,736,035 |
| Options exercisable (in shares) | shares | 20,191,253 |
| Weighted- Average Exercise Price | |
| Outstanding, beginning balance (in dollars per share) | $ / shares | $ 7.38 |
| Granted (in dollars per share) | $ / shares | 3.43 |
| Exercised (in dollars per share) | $ / shares | 2.99 |
| Forfeited (in dollars per share) | $ / shares | 5.73 |
| Outstanding, ending balance (in dollars per share) | $ / shares | 6.54 |
| Weighted- Average Exercise Price, Options exercisable (in dollars per share) | $ / shares | $ 9.82 |
Shareholders’ equity - Schedule of Restricted Share Units Activity (Details) - 2020 Share Option and Incentive Plan - Restricted Share Units (RSUs) |
3 Months Ended |
|---|---|
|
Mar. 31, 2026
$ / shares
shares
| |
| Number of Shares | |
| Outstanding, beginning balance (in shares) | shares | 8,837,384 |
| Granted (in shares) | shares | 4,055,281 |
| Vested and settled (in shares) | shares | (2,416,303) |
| Forfeited (in shares) | shares | (335,734) |
| Outstanding, ending balance (in shares) | shares | 10,140,628 |
| Weighted- Average Grant Date Fair Value | |
| Outstanding, beginning balance (in dollars per share) | $ / shares | $ 4.75 |
| Granted (in dollars per share) | $ / shares | 3.43 |
| Vested and settled (in dollars per share) | $ / shares | 5.51 |
| Forfeited (in dollars per share) | $ / shares | 4.72 |
| Outstanding, ending balance (in dollars per share) | $ / shares | $ 4.04 |
Shareholders’ equity - Additional Information (Details) |
Mar. 31, 2026
shares
|
|---|---|
| 2020 Share Option and Incentive Plan | |
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |
| Number of shares available for issuance (in shares) | 33,758,986 |
Shareholders' equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
| Stock-based compensation expense | $ 12,013 | $ 14,786 |
| Research and development expenses | ||
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
| Stock-based compensation expense | 7,039 | 8,136 |
| Sales, general, and administrative expenses | ||
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
| Stock-based compensation expense | $ 4,974 | $ 6,650 |
Revenue - Schedule of Deferred Revenue Outstanding (Details) - USD ($) $ in Thousands |
Mar. 31, 2026 |
Dec. 31, 2025 |
Mar. 31, 2025 |
Dec. 31, 2024 |
|---|---|---|---|---|
| Revenue from Contract with Customer [Abstract] | ||||
| Deferred revenue | $ 8,993 | $ 17,026 | $ 32,535 | $ 19,221 |
Revenue - Additional Information (Details) - USD ($) $ in Millions |
3 Months Ended | ||
|---|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
Dec. 31, 2025 |
|
| Revenue from Contract with Customer [Abstract] | |||
| Contract with customer liability, revenue recognized | $ 7.9 | $ 2.6 | |
| Proceeds from legal settlements | $ 18.0 | ||
| Litigation settlement receivable | $ 36.0 | ||
Financial instruments - Additional Information (Details) - USD ($) $ in Millions |
Mar. 31, 2026 |
Dec. 31, 2025 |
|---|---|---|
| Investments, All Other Investments [Abstract] | ||
| Long term assets | $ 32.5 | $ 32.5 |
| Term of securities (in years) | 7 months 6 days |
Financial Instruments - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands |
Mar. 31, 2026 |
Dec. 31, 2025 |
|---|---|---|
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | $ 427,669 | $ 405,313 |
| U.S. government agencies | ||
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | 63,482 | |
| Certificate of deposit | ||
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | 105,629 | |
| Commercial paper | ||
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | 41,313 | |
| Corporate bonds | ||
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | 144,774 | |
| Asset backed securities | ||
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | 72,471 | |
| Level 1 | ||
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | 63,482 | |
| Level 1 | U.S. government agencies | ||
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | 63,482 | |
| Level 2 | ||
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | 364,187 | |
| Level 2 | Certificate of deposit | ||
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | 105,629 | |
| Level 2 | Commercial paper | ||
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | 41,313 | |
| Level 2 | Corporate bonds | ||
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | 144,774 | |
| Level 2 | Asset backed securities | ||
| Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
| Marketable securities | $ 72,471 |
Government contributions (Details) $ in Thousands, $ in Millions |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
May 31, 2023 |
Mar. 31, 2026
USD ($)
|
Dec. 31, 2025
USD ($)
|
Dec. 31, 2024
USD ($)
|
Dec. 31, 2024
CAD ($)
|
Mar. 31, 2026
CAD ($)
|
|
| Government Assistance [Line Items] | ||||||
| Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag | Government Contribution 1 (Canada)2 | |||||
| Accounts Receivable | $ 30,202 | $ 33,592 | ||||
| Deferred Government Contribution | 185,053 | 183,436 | ||||
| Accounts Receivable, Current | 17,661 | |||||
| Deferred Government Contribution, Current | 8,948 | |||||
| Accounts Receivable, Long-Term | 12,541 | |||||
| Deferred Government Contributions, Long-Term | 176,105 | 174,453 | ||||
| Non-cash investing activities | 200 | 800 | ||||
| Non-cash financing activities | 4,900 | 8,300 | ||||
| Other Government Grants | ||||||
| Government Assistance [Line Items] | ||||||
| Accounts Receivable | 0 | |||||
| Deferred Government Contribution | 974 | |||||
| Canada | Government Contribution 1 | ||||||
| Government Assistance [Line Items] | ||||||
| Accounts Receivable | 0 | |||||
| Deferred Government Contribution | 78,139 | |||||
| Canada | Government Contribution 2 | ||||||
| Government Assistance [Line Items] | ||||||
| Accounts Receivable | 12,486 | |||||
| Deferred Government Contribution | 81,151 | |||||
| Government assistance, number of times repayable grant | 1.4 | |||||
| Government assistance, award amount, undrawn grant funding | 80,200 | $ 111.8 | ||||
| Funding commitment received | 67,800 | 94.4 | ||||
| Accrued grants receivable | 12,500 | |||||
| British Columbia | Government Contribution 2 | ||||||
| Government Assistance [Line Items] | ||||||
| Accounts Receivable | 17,716 | |||||
| Deferred Government Contribution | 24,789 | |||||
| Government assistance, award amount, undrawn grant funding | 43,200 | 60.2 | ||||
| Funding commitment received | 25,500 | $ 35.5 | ||||
| Accrued grants receivable | 17,700 | |||||
| Non-repayable | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | 13,019 | 13,690 | ||||
| Deferred Government Contribution, Current | 2,299 | |||||
| Deferred Government Contributions, Long-Term | 10,720 | |||||
| Non-repayable | Other Government Grants | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | 974 | |||||
| Non-repayable | Canada | Government Contribution 1 | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | 1,367 | |||||
| Non-repayable | Canada | Government Contribution 2 | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | 10,678 | |||||
| Non-repayable | British Columbia | Government Contribution 2 | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | 0 | |||||
| Conditionally Repayable | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | 101,561 | 103,247 | ||||
| Deferred Government Contribution, Current | 6,649 | |||||
| Deferred Government Contributions, Long-Term | 94,912 | |||||
| Conditionally Repayable | Other Government Grants | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | 0 | |||||
| Conditionally Repayable | Canada | Government Contribution 1 | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | 76,772 | |||||
| Conditionally Repayable | Canada | Government Contribution 2 | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | $ 0 | |||||
| Repayment period | 15 years | |||||
| Conditionally Repayable | British Columbia | Government Contribution 2 | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | $ 24,789 | |||||
| Repayment period | 15 years | |||||
| Repayable | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | $ 70,473 | $ 66,499 | ||||
| Deferred Government Contribution, Current | 0 | |||||
| Deferred Government Contributions, Long-Term | 70,473 | |||||
| Repayable | Other Government Grants | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | 0 | |||||
| Repayable | Canada | Government Contribution 1 | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | 0 | |||||
| Expenditures incurred | $ 88,500 | $ 116.9 | ||||
| Repayable | Canada | Government Contribution 2 | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | $ 70,473 | |||||
| Repayment period | 15 years | |||||
| Repayable | British Columbia | Government Contribution 2 | ||||||
| Government Assistance [Line Items] | ||||||
| Deferred Government Contribution | $ 0 | |||||